TTYH1 Inhibitors
TTYH1 inhibitors, also known as Tweety homolog 1 inhibitors, belong to a class of chemical compounds designed to target and modulate the activity of the TTYH1 protein. TTYH1 is a member of the Tweety family of ion channels, which are known to play a crucial role in regulating ion transport across cell membranes. Specifically, TTYH1 is a chloride ion channel protein that is found in various tissues throughout the body, including the brain, heart, and skeletal muscles. The inhibition of TTYH1 is of interest in the field of molecular biology and pharmacology due to its implications in cellular physiology and the modulation of ion currents.
TTYH1 inhibitors are designed to bind to the TTYH1 protein and alter its function, often by blocking its ion channel activity. This can result in the regulation of chloride ion flux across cell membranes, which can have downstream effects on various cellular processes. While the precise mechanisms and functions of TTYH1 are still under investigation, it is believed to play a role in the regulation of membrane potential and ion homeostasis. Therefore, TTYH1 inhibitors are valuable tools for researchers to study the physiological functions associated with this protein and to explore its relevance in various cellular contexts. The development and study of TTYH1 inhibitors contribute to our understanding of ion channel biology and may have implications for the development of novel strategies in the future.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib mesylate | 220127-57-1 | sc-202180 sc-202180A | 25 mg 100 mg | $44.00 $109.00 | 61 | |
Imatinib inhibits tyrosine kinases, especially Bcr-Abl, by binding to the ATP-binding site, blocking phosphorylation of downstream signaling proteins. It is used for chronic myeloid leukemia (CML) and certain other cancers. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib inhibits multiple kinases, including Raf and VEGFR, to block cell proliferation and angiogenesis. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib is an EGFR tyrosine kinase inhibitor that competes with ATP for binding, inhibiting phosphorylation and downstream signaling pathways. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $116.00 $330.00 $510.00 $816.00 $1632.00 | 10 | |
ABT-199 inhibits Bcl-2, an anti-apoptotic protein, to induce apoptosis in cancer cells. | ||||||
Osimertinib | 1421373-65-0 | sc-507355 | 5 mg | $86.00 | ||
Osimertinib targets mutant forms of EGFR in NSCLC, blocking autophosphorylation and downstream signaling. It is effective against EGFR T790M mutations. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $153.00 | 5 | |
Ibrutinib inhibits Bruton's tyrosine kinase (BTK), disrupting B-cell signaling and proliferation. | ||||||
Rucaparib | 283173-50-2 | sc-507419 | 5 mg | $150.00 | ||
Rucaparib inhibits poly(ADP-ribose) polymerase (PARP), leading to DNA damage accumulation and cell death. It is used in the research of ovarian and prostate cancer with specific genetic mutations. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib targets multiple tyrosine kinases, including Bcr-Abl, Src family kinases, and others. It disrupts signaling pathways in leukemia and solid tumors. | ||||||
MDV3100 | 915087-33-1 | sc-364354 sc-364354A | 5 mg 50 mg | $240.00 $1030.00 | 7 | |
MDV3100 inhibits the androgen receptor (AR) in prostate cancer cells, blocking AR-mediated transcription and cell growth. It is used in the research of metastatic castration-resistant prostate cancer (mCRPC). | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $128.00 $638.00 | 7 | |
Everolimus inhibits mTOR (mammalian target of rapamycin), reducing cell proliferation and angiogenesis. | ||||||